Table 1

Patient baseline characteristics by group

Pre-Intervention

Post-Intervention

Active (n = 33)

Control (n = 36)

Active (n = 23)

Control (n = 29)

Males (%)

62%

51%

Age (years)

61 (10)

66 (13)

Prescribed levodopa (%)

21 (62%)

25 (71%)

18 (78%)

22 (76%)

Levodopa dose (mg)

485 (252)

538 (389)

511 (306)

670 (380)

Prescribed dopamine agonist (%)

25 (74%)

25 (71%)

18 (78%)

18 (62%)

Change in levodopa equivalent units

-

-

51 (148)

70 (149)

Number of PD drugs

2.4 (1.1)

2.4 (1.3)

2.4 (1.2)

2.2 (1.5)

Number of PD daily doses

4.0 (2.5)

4.0 (1.3)

4 (0.8)

4 (1.2)

Number of PD tablets per day

9 (5)

9.1 (5)

9.5 (5)

9 (5)

Number of non-PD drugs per day

2.6 (3)

2.9 (1.8)

2.5 (3)

3.5 (4)

Total number of tablets per day

12 (5)

12 (5)

13 (7)

12 (7)

Number of patients with carer

6 (18%)

7 (19%)

Duration of PD (years)

7.5 (6)

6.3 (4.1)

-

-

UPDRS 3

30 (12)

24 (13)

29 (14)

28 (14)

Hoehn & Yahr

2.4 (0.7)

2.4 (0.7)

2.5 (0.7)

2.5 (0.7)

Schwab & England

78 (10)

76 (14)

71 (18)

73 (15)

MMSE

28 (2)

28 (2)

-

-

Geriatric depression score

12 (6)

10 (7)

-

-

PDQ SI

30 (15)

26.5 (18)

36 (15)

28 (14)

Timing adherence, median (IQ)

17% (9–51)

21% (10–59)

39% (22–58)

20% (10–47)*

Data are mean (standard deviation) unless otherwise stated. PD = Parkinson's disease, UPDRS = Unified Parkinson's disease rating scale, MMSE = mini mental state examination, PDQ 39 SI = Parkinson's disease quality of life single index, IQ = interquartile range. *p = 0.007. There were no other significant differences between groups.

Grosset and Grosset BMC Neurology 2007 7:20   doi:10.1186/1471-2377-7-20